 Connection
David Ivy to Piperazines
This is a "connection" page, showing publications David Ivy has written about Piperazines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.330 |
|
|
|
-
Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014 May 13; 129(19):1914-23.
Score: 0.091
-
Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol. 2012 Jun; 33(5):683-8.
Score: 0.079
-
Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012 Jan 17; 125(2):324-34.
Score: 0.077
-
Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009 Mar; 154(3):379-84, 384.e1-2.
Score: 0.062
-
Maxey DM, Ivy DD, Ogawa MT, Feinstein JA. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients. Pediatr Cardiol. 2013 Oct; 34(7):1628-36.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|